Silver Spring, Maryland, January 17, 2019 – Erik Shoger, dQ&A’s Director of Customer Success, presented patient data on DKA and ketone testing behavior at the sotagliflozin Ad Comm, emphasizing the need for education and training if sotagliflozin is approved. The committee ultimately voted 8-8 on sotagliflozin as a treatment for adults with type 1 diabetes. View our slides below.
Sign up for our newsletter to receive the latest data and news from dQ&A.
